The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Best Overall Response (BOR)
Timeframe: Through study completion, up to approximately 4.9 years
Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
Timeframe: Up to approximately 4.9 years
Overall Survival (OS)
Timeframe: Through study completion, up to approximately 4.9 years
Number of Participants with Adverse Events (AEs)
Timeframe: Up to approximately 4.9 years
Number of Participants with Adverse Reactions (ARs)
Timeframe: Up to approximately 4.9 years